Total trials
317
Active
49
Phase 3
0
Total enrollment
26,416
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fluticasone propionate nasal spray | — | — | — | — | — | 1 | |
| Fluticasone propionate-azelastine nasal spray | — | — | — | — | — | 1 | |
| intracochlear platelet rich fibrin administration | — | — | — | — | — | 1 | |
| Autologous Platelet-Rich Plasma | — | — | — | — | — | 1 | |
| Conditioned serum | — | — | — | — | — | 1 |
Next readouts
- 2023-10-30
- 2026-06-30
- 2028-12-01
Top conditions
- Stroke11
- Multiple Sclerosis6
- Pain6
- Urinary Bladder, Overactive6
- Hand Injuries5
- Cerebral Palsy5
- Low Back Pain4
- Exercise4
Frequently asked questions about Pamukkale University
- How many clinical trials does Pamukkale University have on ClinicalTrials.gov?
- Pamukkale University is listed as the lead sponsor on 317 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Pamukkale University's trials are in Phase 3?
- 0 of Pamukkale University's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Pamukkale University focus on?
- Pamukkale University's most-studied conditions on ClinicalTrials.gov are Stroke, Multiple Sclerosis, Pain, Urinary Bladder, Overactive, Hand Injuries.
- When are Pamukkale University's next clinical trial readouts?
- Pamukkale University has 3 upcoming primary-completion readouts tracked here; the soonest is “INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION”, expected around 2023-10-30.